Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model

The classification of melanoma subtypes into prognostically relevant and therapeutically insightful categories has been a challenge since the first description of melanoma in the 1800s. One limitation has been the assumption that the two most common histological subtypes of melanoma, superficial spreading and nodular, evolve according to a linear model of progression, as malignant melanocytes spread radially and then invade vertically. However, recent clinical, pathological, and molecular data indicate that these two histological subtypes might evolve as distinct entities. Here, we review the published data that support distinct molecular characterization of superficial spreading and nodular melanoma, the clinical significance of this distinction including prognostic relevance and the therapeutic implications.

[1]  G. Schwartz,et al.  Treatment implications of the emerging molecular classification system for melanoma. , 2011, The Lancet. Oncology.

[2]  H. Putter,et al.  Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. , 2011, Journal of the American Academy of Dermatology.

[3]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Zavadil,et al.  miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. , 2011, Cancer cell.

[5]  C. Antonescu,et al.  KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.

[6]  S. Ariyan,et al.  MicroRNA signatures differentiate melanoma subtypes , 2011, Cell cycle.

[7]  L. Poliseno,et al.  Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Choi,et al.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.

[9]  R. Scolyer,et al.  Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care , 2011, Molecular oncology.

[10]  Jiri Zavadil,et al.  Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. , 2011, Cancer research.

[11]  Ali Nahvi,et al.  A Parsimonious Model for Gene Regulation by miRNAs , 2011, Science.

[12]  Mustafa Sahin,et al.  MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. , 2010, Cell stem cell.

[13]  D. Schadendorf,et al.  Genetic and morphologic features for melanoma classification , 2010, Pigment cell & melanoma research.

[14]  J. O'Brien,et al.  Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.

[15]  S. Dacic,et al.  miRNA expression profiling of lung adenocarcinomas: correlation with mutational status , 2010, Modern Pathology.

[16]  Kenneth S Kosik,et al.  MicroRNAs and Cellular Phenotypy , 2010, Cell.

[17]  F. Hodi,et al.  Advances in targeted therapy for melanoma. , 2010, Clinical advances in hematology & oncology : H&O.

[18]  M. Zappa,et al.  The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past , 2010, Melanoma research.

[19]  K. Katsuoka,et al.  Nestin is expressed in HMB‐45 negative melanoma cells in dermal parts of nodular melanoma , 2010, The Journal of dermatology.

[20]  L. Chin,et al.  Integrative Genome Comparison of Primary and Metastatic Melanomas , 2010, PloS one.

[21]  Y. Pekarsky,et al.  Reprogramming of miRNA networks in cancer and leukemia. , 2010, Genome research.

[22]  T. Venesio,et al.  Altered molecular pathways in melanocytic lesions , 2010, International journal of cancer.

[23]  M. Weinstock,et al.  Melanoma thickness trends in the United States, 1988-2006. , 2010, The Journal of investigative dermatology.

[24]  Yingdong Zhao,et al.  MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer , 2010, Clinical Cancer Research.

[25]  D. Jukic,et al.  Microrna profiling analysis of differences between the melanoma of young adults and older adults , 2010, Journal of Translational Medicine.

[26]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N. Tanna,et al.  Comparative genomic hybridization for the diagnosis of melanoma , 2009, European Journal of Plastic Surgery.

[28]  J. Reis-Filho,et al.  Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.

[29]  Myles G Cockburn,et al.  Increasing burden of melanoma in the United States. , 2009, The Journal of investigative dermatology.

[30]  D. Silvers,et al.  GAB2 Amplifications Refine Molecular Classification of Melanoma , 2009, Clinical Cancer Research.

[31]  Emmanuel Barillot,et al.  Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. , 2009, Investigative ophthalmology & visual science.

[32]  S. Swetter,et al.  Factors related to the presentation of thin and thick nodular melanoma from a population‐based cancer registry in Queensland Australia , 2009, Cancer.

[33]  Michael Schmidt,et al.  Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype , 2009, Melanoma research.

[34]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[35]  Claus Garbe,et al.  Melanoma epidemiology and trends. , 2009, Clinics in dermatology.

[36]  M. Mazumdar,et al.  Changes in the presentation of nodular and superficial spreading melanomas over 35 years , 2008, Cancer.

[37]  M. Mazumdar,et al.  Shedding of Distinct Cryptic Collagen Epitope (HU177) in Sera of Melanoma Patients , 2008, Clinical Cancer Research.

[38]  A. Reeder,et al.  The incidence and thickness of cutaneous malignant melanoma in New Zealand 1994-2004. , 2008, The New Zealand medical journal.

[39]  K. Flaherty,et al.  Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. , 2008, Cancer research.

[40]  W. Gerald,et al.  Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.

[41]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[42]  E. Herrera‐Ceballos,et al.  Thick melanoma: the problem continues , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[43]  A. de Klein,et al.  Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome. , 2008, Cancer genetics and cytogenetics.

[44]  Valerie Speirs,et al.  A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer , 2008, Breast Cancer Research and Treatment.

[45]  D. Polsky,et al.  BAY 43-9006 (sorafenib-BAY) alters proliferation pathways and mutant specific-PCR (MS-PCR) improves detection of BRAF mutations in metastatic melanoma (MM) , 2007 .

[46]  S. Formenti,et al.  Disruption of Endothelial Cell Interactions with the Novel HU177 Cryptic Collagen Epitope Inhibits Angiogenesis , 2007, Clinical Cancer Research.

[47]  R. Millikan,et al.  Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[48]  R. Spang,et al.  Gene Expression Signatures for Tumor Progression, Tumor Subtype, and Tumor Thickness in Laser-Microdissected Melanoma Tissues , 2007, Clinical Cancer Research.

[49]  M. Trivett,et al.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.

[50]  L. Chin,et al.  Growth factors and oncogenes as targets in melanoma: lost in translation? , 2007, Advances in dermatology.

[51]  Shuping Zhao,et al.  Increased expression of stem cell markers in malignant melanoma , 2007, Modern Pathology.

[52]  J. Lundeberg,et al.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.

[53]  Jason S. White,et al.  Correlation of comparative genomic hybridization results of 100 archival uveal melanomas with patient survival. , 2006, Cancer genetics and cytogenetics.

[54]  G. Saldanha,et al.  Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies , 2006, Clinical Cancer Research.

[55]  M. Meyerson,et al.  Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[56]  M. Atkins,et al.  Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.

[57]  M. Demierre Epidemiology and prevention of cutaneous melanoma , 2006, Current treatment options in oncology.

[58]  S. Formenti,et al.  Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. , 2006, The American journal of pathology.

[59]  M. Ladanyi,et al.  Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[60]  B. Bastian,et al.  Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool , 2006, Dermatologic therapy.

[61]  J. A. Burch,et al.  Melanoma, a tumor based on a mutant stem cell? , 2006, The Journal of investigative dermatology.

[62]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[63]  H. Yee,et al.  Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. , 2005, The American journal of pathology.

[64]  R. Houlston,et al.  Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3 , 2005, British Journal of Cancer.

[65]  R. MacKie,et al.  Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. , 2005, The Journal of investigative dermatology.

[66]  A. Kopf,et al.  ABCDE--an evolving concept in the early detection of melanoma. , 2005, Archives of dermatology.

[67]  Donald R. Miller,et al.  Early detection of thick melanomas in the United States: beware of the nodular subtype. , 2005, Archives of dermatology.

[68]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[70]  Kazuhiro Takahashi,et al.  BRAF point mutations in primary melanoma show different prevalences by subtype. , 2004, The Journal of investigative dermatology.

[71]  G. Reifenberger,et al.  Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas , 2004, International journal of cancer.

[72]  M. Frazier,et al.  Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[74]  L. Kanter,et al.  NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  A. Pardee,et al.  Analysing differential gene expression in cancer , 2003, Nature Reviews Cancer.

[76]  B. Mcavoy,et al.  Nodular melanoma. No longer as simple as ABC. , 2003, Australian family physician.

[77]  Lin Fritschi,et al.  Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection. , 2003, Journal of the American Academy of Dermatology.

[78]  P. Carli,et al.  Unexpected reduction of mortality rates from melanoma in males living in central Italy. , 2003, European journal of cancer.

[79]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[80]  N. Hayward,et al.  Loss of p16 expression is associated with histological features of melanoma invasion , 2002, Melanoma research.

[81]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[82]  P. Meltzer,et al.  A genome-based strategy uncovers frequent BRAF mutations in melanoma. , 2002, Cancer cell.

[83]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[84]  T. Golub,et al.  DNA microarrays in clinical oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[86]  Jingsong Xu,et al.  Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo , 2001, The Journal of cell biology.

[87]  R. Ádány,et al.  Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. , 2001, Cytometry.

[88]  Emanuel Petricoin,et al.  Molecular profiling of human cancer , 2000, Nature Reviews Genetics.

[89]  D. Lipsker,et al.  Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. , 1999, Archives of dermatology.

[90]  J. Radhi Malignant Melanoma Arising from Nevi, p53, p16, and Bcl-2: Expression in Benign versus Malignant Components , 1999, Journal of cutaneous medicine and surgery.

[91]  D. Wong,et al.  p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma , 1998, Journal of cutaneous pathology.

[92]  Y. Collan,et al.  Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage , 1997, International journal of cancer.

[93]  T. Saida,et al.  Immunohistochemical detection of CDK4 and 9 16INK4 proteins in cutaneous malignant melanoma , 1996, The British journal of dermatology.

[94]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[95]  G. Burg,et al.  Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. , 1995, Journal of cancer research and clinical oncology.

[96]  S. van der Flier,et al.  Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[97]  J. Hoeffler,et al.  Ras mutations in human melanoma: a marker of malignant progression. , 1994, The Journal of investigative dermatology.

[98]  M. Mihm,et al.  The histopathology of cutaneous malignant melanoma. , 1993, Seminars in diagnostic pathology.

[99]  L. J. Veer,et al.  N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.

[100]  C. Cordon-Cardo,et al.  Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. , 1989, Oncogene.

[101]  L. Old,et al.  Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? , 1984, Nature.

[102]  A. Ackerman Malignant melanoma: a unifying concept. , 1980, Human pathology.

[103]  Ackerman Ab Malignant melanoma. A unifying concept. , 1980 .

[104]  W. Clark,et al.  The classification of malignant melanoma and its histologic reporting , 1973, Cancer.

[105]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[106]  MOLES AND MALIGNANT MELANOMA: TERMINOLOGY AND CLASSIFICATION , 1967, The Medical journal of Australia.